向榮生醫科技股份有限公司
向榮生醫科技股份有限公司在台灣及日本從事幹細胞藥物之研發。開發 ELIXCYTE 用於治療膝骨關節炎與慢性腎臟病，並經營異體脂肪幹細胞庫。提供自體幹細胞治療、細胞衍生分泌物 (Conditioned Medium)、CDMO 委託開發製造、超低溫生物樣本儲存管以及實驗室檢測服務。公司成立於 2011 年，總部位於台灣台北市。
該股 RSI(6) 為 35.3，處於中性區間，短線無明顯超買超賣訊號。股價站上5日均線，跌破20日、60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標中性（K=30.1）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-11 | -4 | 0 | 0 | -4 |
| 08-10 | -8 | 0 | 0 | -8 |
| 08-07 | -10 | 0 | -3 | -13 |
| 08-06 | +3 | 0 | 0 | +3 |
| 08-05 | -23 | 0 | 0 | -23 |
| 08-04 | -10 | 0 | -1 | -11 |
| 08-03 | -6 | 0 | -2 | -8 |
| 07-31 | +7 | 0 | 0 | +7 |
| 07-30 | +1 | 0 | -4 | -3 |
| 07-29 | +7 | 0 | 0 | +7 |
| 07-28 | -2 | 0 | +5 | +3 |
| 07-27 | +6 | 0 | 0 | +6 |
| 07-24 | 0 | 0 | 0 | 0 |
| 07-23 | -23 | 0 | 0 | -23 |
| 07-22 | -4 | 0 | -1 | -5 |
| 07-21 | -3 | 0 | 0 | -3 |
| 07-20 | +1 | 0 | 0 | +1 |
| 07-17 | +9 | 0 | +1 | +10 |
| 07-16 | -1 | 0 | 0 | -1 |
| 07-15 | -4 | 0 | -1 | -5 |
| 07-14 | +7 | 0 | +1 | +8 |
| 07-13 | -13 | 0 | 0 | -13 |
| 07-09 | +6 | 0 | 0 | +6 |
| 07-08 | -8 | 0 | 0 | -8 |
| 07-07 | +57 | 0 | 0 | +57 |
| 07-06 | -3 | 0 | 0 | -3 |
| 07-03 | +4 | 0 | 0 | +4 |
| 07-02 | +3 | 0 | 0 | +3 |
| 07-01 | +2 | 0 | 0 | +2 |
| 06-30 | +15 | 0 | 0 | +15 |
| 06-29 | +10 | 0 | 0 | +10 |
| 06-26 | 0 | 0 | -1 | -1 |
| 06-25 | 0 | 0 | 0 | 0 |
| 06-24 | -5 | 0 | 0 | -5 |
| 06-22 | 0 | 0 | 0 | 0 |
| 06-18 | -7 | 0 | 0 | -7 |
| 06-17 | -17 | 0 | 0 | -17 |
| 06-16 | +5 | 0 | 0 | +5 |
| 06-15 | -2 | 0 | +1 | -1 |
| 06-12 | -4 | 0 | +2 | -2 |
| 06-10 | -13 | 0 | -1 | -14 |
| 06-09 | -3 | 0 | 0 | -3 |
| 06-08 | -2 | 0 | 0 | -2 |
| 06-04 | -6 | 0 | +1 | -5 |
| 06-03 | +10 | 0 | -2 | +8 |
| 06-02 | +1 | 0 | 0 | +1 |
| 06-01 | +19 | 0 | +1 | +20 |
| 05-29 | +6 | 0 | 0 | +6 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/06 | 128 萬 | -10.5% | -43.0% |
| 2026/05 | 142 萬 | -24.8% | +52.4% |
| 2026/04 | 189 萬 | +1.3% | -65.5% |
| 2026/03 | 187 萬 | -28.9% | -66.4% |
| 2026/02 | 263 萬 | +47.8% | +186.2% |
| 2026/01 | 178 萬 | -15.4% | -47.2% |
| 2025/12 | 210 萬 | +8.4% | -65.2% |
| 2025/11 | 194 萬 | -16.0% | -10.1% |
| 2025/10 | 231 萬 | +69.5% | -11.8% |
| 2025/09 | 136 萬 | +54.4% | -76.9% |
| 2025/08 | 88 萬 | -70.4% | -85.7% |
| 2025/07 | 299 萬 | - | +14.8% |